Drugs / Meropenem for Injection
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06198764 Background | Jul 2023 → Mar 2026 | mental disorder | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meropenem for Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06198764 ↗ |
| Action | Inhibit | “inhibits the synthesis of bacterial cell walls” NCT06198764 ↗ |
| Route | Intravenous | “Meropenem intravenous infusion once every 8 hours or 12 hours.” NCT06198764 ↗ |